Table 5. Oncological outcomes (N=150).
| Characteristics | CRC | AC (PMCA + PCA) | AC (DPAM) | GC (P) | GC (T) | OC | OT |
|---|---|---|---|---|---|---|---|
| OS | |||||||
| Median, months | 35 | 82 | − | 18 | 9 | 47 | 51 |
| 5-year, % | 27 | 67 | 100 | 36 | 29* | 48 | 40 |
| DFS | |||||||
| Median, months | 14 | 5 | − | 12 | 4 | 19 | 17 |
| 5-year, % | 22 | 67 | 100 | 46 | 32* | 11 | 29 |
*, 3-year overall survival (OS); P, prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC); T, therapeutic HIPEC; CRC, colorectal cancer; AC, appendiceal cancer; GC, gastric cancer; OC, ovarian cancer; OT, others tumors; DFS, disease free survival; PMCA, peritoneal mucinous carcinomatosis; PCA, high-grade nonmucinous carcinoma; DPAM, disseminated peritoneal adenomucinosis.